Skip to main content

Remote Job Finders (RJF)

Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.

Obesity ends oncology’s long reign as top contributor to biopharma pipeline value

In its latest biopharma pipeline report, Deloitte warned that the growing importance of a small pool of potential mega-blockbusters raises the risk of “significant value destruction from a single program failure.”

Amgen positions MariTide as potential ‘best monthly’ obesity drug

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or more infrequent dosing schedules.
Scroll to top